(MedPage Today) — TORONTO — A substantial proportion of multiple myeloma patients undergoing treatment with bispecific antibodies had sustained remissions when they discontinued therapy before disease progression, according to research presented…
Source link : https://www.medpagetoday.com/meetingcoverage/ims/117532
Author :
Publish date : 2025-09-18 19:17:00
Copyright for syndicated content belongs to the linked Source.
